A Phase 1 Trial of Everolimus and Bevacizumab in Children with Recurrent Solid Tumors

BACKGROUND: Prognosis for children with recurrent solid tumors is generally poor. Targeting mammalian target of rapamycin (mTOR) and vascular endothelial growth factor A with everolimus and bevacizumab, respectively, synergistically improves progression-free survival and is well tolerated in adults...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer
Prif Awduron: Santana, Victor M., Sahr, Natasha, Tatevossian, Ruth G., Jia, Sujuan, Campagne, Olivia, Sykes, April, Stewart, Clinton F., Furman, Wayne L., McGregor, Lisa M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7103504/
https://ncbi.nlm.nih.gov/pubmed/31967673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32722
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg